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Growth hormone-releasing hormone (GHRH) antagonist MIA-690 and GHRH agonist MR-409, 
previously synthesized and developed by us have demonstrated potent antitumor effects. However, 
little is known about the effects of these analogs on brain functions. We investigated the potential 
antinflammatory and antioxidant effects of GHRH antagonist MIA-690 and GHRH agonist MR-409, on 
isolated mouse prefrontal cortex specimens treated with lipopolysaccharide (LPS). Additionally, we 
studied their effects on emotional behavior after chronic in vivo treatment. Ex vivo, MIA-690 and MR-
409 inhibited LPS-induced inflammatory and pro-oxidative markers. In vivo, both MIA-690 and MR-409 
induced anxiolytic and antidepressant-like effects, increased norepinephrine and serotonin levels and 
decreased nuclear factor-kB, tumor necrosis factor-α and interleukin-6 gene expression in prefrontal 
cortex. Increased nuclear factor erythroid 2–related factor 2 expression was also found in mice treated 
with MIA-690 and MR-409. MIA-690 showed higher efficacy in inhibiting all tested inflammatory and 
oxidative markers. In addition, MR-409 induced a down regulation of the gene and protein expression 
of pituitary-type GHRH-receptor in prefrontal cortex of mice after 4 weeks of treatment at 5 µg/day. In 
conclusion, our results demonstrate anxiolytic and antidepressant-like effects of GHRH analogs that 
could involve modulatory effects on monoaminergic signaling, inflammatory and oxidative status.
Growth hormone (GH)-releasing hormone (GHRH) is a neurosecretory peptide produced by hypothalamic neu-
rons which stimulates synthesis and release of GH in the anterior pituitary gland1,2. In addition to its recognized 
metabolic and endocrine effects, GHRH exerts also various effects on central and peripheral tissues such as brain, 
gastrointestinal tract, heart, kidney and retina3–5. In the pituitary, as well as in peripheral tissues, GHRH binds to 
pituitary-type GHRH-receptor (P GHRH-R), a G protein-coupled receptor which stimulates the adenylyl cyclase, 
cAMP and protein kinase A (PKA) cascade6, and to its splice variant (SV1)1,7–9.
Various GHRH receptor agonist and antagonist peptides have been synthesized by us and other groups and 
studied for their biological activity1,10–16. In particular, the novel GHRH antagonists of the Miami (MIA) series, 
MIA-690 and MIA-602, were found to inhibit growth of different human cancer lines and xenografted into nude 
mice in microgram doses after subcutaneous administration15,17,18. The most potent antitumor analogs, MIA-
690 and MIA-602 also showed antinflammatory activities15. However the MIA-series of GHRH analogs with 
increased GHRH-R binding affinity have a weak GH inhibitory activity on pituitary somatotrophs15. GHRH 
agonists of MR series, such as MR-409, exhibit higher potency upon subcutaneous administration and binding 
activity than the parent hormone14,17. Recently, MR-409, a GHRH agonist, was found to inhibit in vivo growth of 
lung cancer xenografted into nude mice14,16. The antinflammatory and antioxidant properties of MR-409 could 
be implicated in these effects. In addition, a GHRH agonist, JI-34, was found to induce anxiety and depression 
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whereas MZ-4-71, a GHRH antagonist, elicited anxiolytic and anti-depressant effects19,20. In addition, we previ-
ously found that mice with GH deficiency due to removal of GHRH gene (GHRHKO) had decreased anxiety- 
and depression-related behaviour21. The aim of our work was to investigate the potential anti-inflammatory and 
antioxidant effects of GHRH antagonist MIA-690 and agonist MR-409 in the brain, and the role of both classes of 
analogs on emotional behavior in adult mice.
Results
Inhibitory effects of MIA-690 and MR-409 on LPS-induced prostaglandin (PG)E2 and 8-iso-
PGF2α levels in prefrontal cortex specimens. Tissue supernatants PGE2 and 8-iso-PGF2α levels were 
determined by radioimmunoassay (RIA), after treatment of prefrontal cortex specimens with LPS + MIA-690 
(1–5 μM), LPS + MR-409 (1–5 μM), LPS or vehicle. Treatment with LPS induced a significant increase of PGE2 
and 8-iso-PGF2α levels in prefrontal cortex specimens, as compared to vehicle treated controls. The GHRH antag-
onist MIA-690 (1–5 μM) and GHRH agonist MR-409 (1–5 μM) were found to inhibit LPS-induced PGE2 and 
8-iso-PGF2α levels in a dose-dependent manner [Fig. 1 panel A and B; F2/12 = 3.11, p < 0.05 and F2/12 = 6.93, 
p < 0.01 (for MIA-690); F2/12 = 5.10, p < 0.005 and F2/12 = 12.97, p < 0.001 (for MR-409)]. In this context, MR-409 
(1–5 μM) was more effective than MIA-690 in decreasing LPS-induced PGE2 and 8-iso-PGF2α levels [Fig. 1 panel 
A and B; F2/12 = 3.11, p < 0.05].
Inhibitory effects of MIA-690 and MR-409 on LPS-induced lactate dehydrogenase (LDH) and 
nitrite production in prefrontal cortex specimens. In order to evaluate potential effects of MIA-690 
(1–5 μM) and MR-409 (1–5 μM) on oxidative stress biomarkers, we measured LPS-induced LDH and nitrite 
production in prefrontal cortex specimens treated with the peptides. LPS treatment induced a significant increase 
of LDH and nitrite production in prefrontal cortex specimens, as compared to vehicle treated controls. MIA-
690 (1–5 μM) decreased LDH activity and nitrite levels in a dose-dependent manner [Fig. 2 panel A and B; 
F4/14 = 5.04, p < 0.01 and F4/14 = 3.89, p < 0.005]. Similarly, MR-409 (1–5 μM) inhibited LPS-induced LDH activ-
ity and nitrite levels, without showing a dose-dependent effect [Fig. 2 panel A and B; F4/12 = 4.47, p < 0.05 and 
F4/12 = 5.41, p < 0.01]. MIA-690 (1–5 μM) was more effective in decreasing LPS-induced LDH and nitrite produc-
tion compared to MR-409 [Fig. 2 panel A and B; F4/14 = 3.11, p < 0.05 and F4/14 = 3.89, p < 0.005].
MIA-690 and MR-409 decrease LPS- induced cyclooxygenase-2 (COX-2), nuclear factor-kB 
(NF-kB) and inducible nitric oxide synthase (iNOS) gene expression in prefrontal cortex spec-
imens. Real-time polymerase chain-reaction (PCR) revealed a significantly increase in COX-2, NF-kB and 
iNOS gene expression in prefrontal cortex specimens after LPS treatment, as compared to vehicle treated controls. 
The GHRH antagonist MIA-690 (1–5 μM) inhibited LPS-induced inflammatory markers in a dose-dependent 
manner in prefrontal cortex specimens [Fig. 3 panel A, B and C; F6/18 = 2.66, p < 0.05 and F6/18 = 6.01, p < 0.01]. 
Our findings also showed that the GHRH agonist MR-409 (1–5 μM) inhibited LPS-induced COX-2, NF-kB and 
iNOS gene expression in prefrontal cortex specimens, without a dose-dependent effect [Fig. 3 panel A, B and 
C; F5/15 = 2.90, p < 0.05]. MIA-690 (5 μM) was more effective than MR-409 in decreasing all the markers tested 
[Fig. 3 panel A, B and C; F6/18 = 2.66, p < 0.05].
Exploration behavioral analysis. Horizontal and vertical activity was recorded in the home cage over 
10 min. MIA-690 (5 μg) or MR-409 (5 μg) was s.c. injected daily for 4 weeks in mice. Control animals received 
Figure 1. Inhibitory effects of MIA-690 (1–5 μM) and MR-409 (1–5 μM) on PGE2 and 8-iso-PGF2α levels, ex 
vivo (n = 5 for each group of treatment). Data are expressed as means ± S.E.M. and analyzed by analysis of 
variance (ANOVA) followed by Bonferroni post-hoc test *p < 0.05, **p < 0.01,***p < 0.005; ****p < 0.001 vs. 
LPS group; #p < 0.05 vs. co-respective treatment with MIA-690.
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Figure 2. Inhibitory effects of MIA-690 (1–5 μM) and MR-409 (1–5 μM) on LDH and nitrite production, ex 
vivo (n = 5 for each group of treatment). Data are expressed as means ± S.E.M. and analyzed by analysis of 
variance (ANOVA) followed by Bonferroni post-hoc test *p < 0.05, **p < 0.01,***p < 0.005 vs LPS group; 
#p < 0.05 and ##p < 0.005 vs. co-respective treatment with MR-409.
Figure 3. Relative quantification of COX-2, NF-kB and iNOS gene expression in mouse prefrontal cortex 
specimens treated with MIA-690 (1–5 μM) and MR-409 (1–5 μM), ex vivo (n = 5 for each group of treatment). 
Data were calculated using the 2−ΔΔCt method, normalized to β-actin mRNA levels, and expressed relative to 
control (calibrator sample, defined as 1.00). Data are expressed as means ± S.E.M. and analyzed by analysis of 
variance (ANOVA) followed by Bonferroni post-hoc test *p < 0.05, **p < 0.01 vs. LPS group; #p < 0.05 vs. co-
respective treatment with MR-409.
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s.c. injection of vehicle [0.1% DMSO (Sigma) and 10% propylene glycol]. As shown in Fig. 4, s.c. administration 
of MIA-690 (5 μg) and MR-409 (5 μg) did not modify locomotor activity respect to vehicle injected animals. 
Two-way ANOVA did not show significant differences in horizontal (Fig. 4 panel A; 2 wk F2/27 = 3.27, p = 0.57; 
4 wk F2/27 = 0.11, p = 0.89) and vertical activity (Fig. 4 panel B; 2 wk F2/27 = 3.15, p = 0.058; 4 wk F2/27 = 0.57, 
p = 0.56) at 2 and 4 weeks of treatment, with respect to controls.
Anxiety-like behavior. To evaluate the possible effects of MIA-690 (5 μg) and MR-409 (5 μg) on anxiety-like 
behavior, light-dark box and elevated plus maze test were used. The evaluations were performed at 2 and 4 weeks 
of treatment. We found that s.c. injection of MIA-690 (5 μg) or MR-409 (5 μg) decreased anxiety related behavior 
(Figs. 5 and 6) at 2 and 4 weeks of treatment, for MIA-690, and at 4 weeks of treatment for MR-409. Compared 
to vehicle, treatment with MIA-690 and MR-409 increased time spent in the light area [Fig. 5 panel A; 2 wk 
F9/9 = 2.73, p < 0.005; 4 wk F9/9 = 3.33, p < 0.005 (for MIA-690); 4 wk F9/9 = 1.64 p < 0.01 (for MR-409)] and open 
arms [Fig. 6 panel A; 2 wk F9/9 = 3.30, p < 0.005; 4 wk F9/9 = 2.56, p < 0.005 (for MIA-690); 4 wk F9/9 = 1.47, 
p < 0.05 (for MR-409)] in light-dark and elevated plus maze, respectively. Both peptides decreased latencies to 
emerge from enclosed dark compartment in the light-dark box [Fig. 5 panel B; 2 wk F9/9 = 2.21, p < 0.005; 4 
wk F9/9 = 1.76 p < 0.005(for MIA-690); 4 wk F9/9 = 1.11, p < 0.01 (for MR-409)] and from the central zone in 
the elevated plus maze [Fig. 6 panel B; 2 wk F9/9 = 3.46, p < 0.005; 4 wk F9/9 = 23.61, p < 0.005 (for MIA-690); 
4 wk F9/9 = 6.35, p < 0.01 (for MR-409)]. General activity, measured as the number of the total transitions, was 
not changed in both tests [Fig. 5 panel C; 2 wk F9/9 = 2.53, p = 0.18; 4 wk F9/9 = 3.61, p = 0.6 (for MIA-690); 2 
wk F9/9 = 2.33, p = 0.22; 4 wk F9/9 = 1.45, p = 0.58 (for MR-409); Fig. 6 panel C; 2 wk F9/9 = 1.45, p = 0.58; 4 wk 
F9/9 = 3.61, p = 0.6 (for MIA-690); 2 wk F9/9 = 1.34, p = 0.6; 4 wk F9/9 = 1.58, p = 0.51 (for MR-409)].
In both tests, MIA-690 was more effective than MR-409 in decreasing anxiety related behavior [Fig. 5; 
2 wk F2/27 = 26.87, p < 0.005; 4 wk F2/27 = 23.31, p < 0.05 (light area) and 2 wk F2/27 = 76.75, p < 0.005; 4 wk 
F2/27 = 23.31, p < 0.05 (latency to first exit) for light-dark exploration test] [Fig. 6; 2 wk F2/27 = 28.88, p = 0.001; 
4 wk F2/27 = 30.59, p = 0.05 (open arms) and 2 wk F2/27 = 40.17, p < 0.005; 4 wk F2/27 = 76.64, p < 0.05 (latency to 
first exit) for elevated plus maze test].
Behavioral despair. To evaluate the possible effects of MIA-690 (5 μg) and MR-409 (5 μg) on behavioral despair, 
the tail suspension test was used. The evaluations were performed at 2 and 4 weeks of treatment. Figure 7 shows 
total immobility time in tail suspension test. MIA-690 (5 μg) and MR-409 (5 μg) s.c. injection induced a signifi-
cant decrease of total immobility (Fig. 7) at 2 and 4 weeks of treatment, for MIA-690, and at 4 weeks of treatment 
for MR-409 [Fig. 7; 2 wk F9/7 = 11.10, p < 0.005; 4 wk F9/7 = 2.01, p < 0.005 (for MIA-690); 4 wk F9/7 = 16.14, 
p = 0.01 (for MR-409)]. In the tail suspension test, MIA-690 was more effective than MR-409 on inducing immo-
bility (Fig. 7; 2 wk F2/23 = 52.48, p < 0.005; 4 wk F0/0 = 51.59, p = 0.05).
Monoamine levels in prefrontal cortex. To further evaluate the possible mechanisms involved in emotional 
behavior, we measured monoamine levels in prefrontal cortex by HPLC. Table 1 shows an increase in norepineph-
rine (NE) and serotonin (5-hydroxytryptamine, 5-HT) levels in prefrontal cortex of mice treated with MIA-690 
Figure 4. Locomotor activity in mice treated with MIA 690 (5 μg) and MR 409 (5 μg) (n = 18 for each group 
of treatment). Compared to vehicle, MIA-690 and MR-409 treatment did not change locomotor activity. 
Horizontal activity (A) and vertical activity (B) were recorded for 10 min. Data are expressed as means ± S.E.M. 
and analyzed by analysis of variance (ANOVA) followed by Bonferroni post-hoc test.
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(5 μg) and MR-409 (5 μg), [F3/9 = 6.99, p < 0.005 and F3/9 = 13.90, p < 0.001] without any affect on dopamine (DA) 
levels, as compared to controls [F2/27 = 3.27, p = 0.57]. In addition, the increase in NE and 5-HT levels was greater 
with MIA-690 respect to MR-409 [F3/9 = 3.86, p < 0.005].
MIA-690 and MR-409 decreased NF-kB, tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 
gene expression in mice prefrontal cortex. Real-time polymerase chain-reaction (PCR) revealed a sig-
nificant decrease in NF-kB, TNF-α and IL-6 gene expression after MIA-690 (5 μg) and MR-409 (5 μg) treatment 
in prefrontal cortex, in mice [F2/16 = 2.85, p < 0.05 and F2/16 = 10.97, p < 0.001]. MIA-690 was more effective than 
MR-409 in decreasing NF-kB, TNF-α and IL-6 [Fig. 8 panel A, B and C; F5/16 = 2.85, p < 0.05].
Haematoxylin-eosin staining and immunohistochemical analysis of nuclear factor erythroid 
2–related factor 2 (Nrf2) in mouse prefrontal cortex. Morphological features and detection of Nrf2 in 
prefrontal cortex have been analyzed by hematoxylin-eosin (H&E) staining and immunohistochemistry, respec-
tively. H&E stained sections of the (a) control (ctrl), (b) MIA-690 and (c) MR-409 mice showed the normal his-
tological structure of prefrontal cortex. The frontal cortex appeared laminated with six different layers of variable 
thickness that are blended with each other (Fig. 9, panel A: a, b and c).
Immunohistochemical examination revealed positive immunostaining for Nrf2 expression in mice exposed 
for 4 weeks to subcutaneous chronic treatment (a) positive vehicle (ctrl); (b) mice treated with MIA-690; (c) mice 
treated with MR-409 (Fig. 9, panel B: a, b, c and d). As compared to the control, increased Nrf2 immunostaining 
was detected in mice treated with MIA-690 or MR-409 [Fig. 9 panel C; F2/15 = 2.79, p < 0.05 and F2/15 = 11.34, 
p < 0.01]. Our findings also showed that MIA-690 increased immunoreactivity for Nrf2 respect to MR-409 [Fig. 9 
panel C; F2/15 = 6.36, p < 0.01].
MR-409 induced down regulation of P GHRH-R gene and protein expression in prefrontal cor-
tex. We finally evaluated the effects of MIA-690 (5 μg) and MR-409 (5 μg) treatment on P GHRH-R gene and 
protein expression in prefrontal cortex. Compared to vehicle treated mice, subcutaneous injection of MR-409 
induced a significant reduction in P GHRH-R gene and protein expression in prefrontal cortex after 4 weeks of 
treatment [Fig. 10; F2/15 = 2.79, p < 0.005; Fig. 11; F2/6 = 0.79, p < 0.05] (Supplementary Figs. S1 and S2).
Figure 5. Analysis of anxiety-related behavior in mice treated with MIA-690 (5 μg) or MR-409 (5 μg) (n = 18 
for each group of treatment). Compared to vehicle, MIA-690 (2–4 wk) and MR-409 (4 wk) decreased anxiety-
like behavior in light-dark box. MIA-690 was more effective than MR-409 (2–4 wk). Data are expressed 
as means ± S.E.M. and analyzed by analysis of variance (ANOVA) followed by Bonferroni post-hoc test 
**p < 0.01,***p < 0.005 vs. control; #p < 0.05 and ##p < 0.005 vs. MR-409 treated mice.
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Discussion
GHRH and mRNAs for GHRH-R have been found in rat cortex and brain stem22,23, and various reports sug-
gested that GHRH might play a key role in cognitive and mood disorders20,24–28. GHRH-antagonists compounds 
can exert powerful antitumor effects, possibly related in part to their antinflammatory and antioxidant proper-
ties17,29–33. In the present study we show that MIA-690, a GHRH antagonist, and MR-409, a GHRH analog, exhibit 
antinflammatory and antioxidant effects on prefrontal cortex specimens, ex vivo (Figs. 1, 2 and 3). Accordingly, 
various studies showed that GHRH and GHRH antagonists can influence the inflammatory and reduction/oxi-
dation (redox) status in cancer and other tissues29,33.
Figure 6. Analysis of anxiety-related behavior in mice treated with 5 μg MIA-690 or 5 μg MR-409 (n = 18 for 
each group of treatment). Compared to the vehicle, MIA-690 (2–4 wk) and MR-409 (4 wk) decreased anxiety-
like behavior in elevated plus maze test. MIA-690 was more effective than MR-409 (2–4 wk). Data are expressed 
as means ± S.E.M. and analyzed by analysis of variance (ANOVA) followed by Bonferroni post-hoc test 
*p < 0.05, ***p < 0.005 vs. control; #p < 0.05, ##p < 0.005 and ###p < 0.001 vs. MR-409 treated mice.
Figure 7. Behavioral despair measured in tail suspension test in mice treated with 5 μg MIA-690 and 5 μg 
MR-409 (n = 18 for each group of treatment). Compared to vehicle, MIA-690 (2–4 wk) and MR-409 (4 wk) 
decreased behavioral despair. MIA-690 was more effective than MR-409 (2–4 wk). Data are expressed as 
means ± S.E.M. and analyzed by analysis of variance (ANOVA) followed by Bonferroni post-hoc test **p < 0.01, 
***p < 0.005 vs. control; #p < 0.05 and ##p < 0.005 vs. MR-409 treated mice.
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In particular, MIA 690 decreased inflammation by reducing the infiltration of macrophages and leucocytes, 
the production of TNF-α, IL-1β, and monocyte chemotactic protein-1 (MCP-1) in tissue after insult with lipopo-
lisaccaride (LPS) and the production of the pro-inflammatory markers in carrageenan-induced chronic pros-
tatis31,32. In addition, MIA-690 showed antioxidant and neuroprotective properties28. In a model of Alzheimer’s 
disease as well as in cancer and other tissues, MR-409 has been described to exert antinflammatory and antioxi-
dant effects, as well as in early experimental diabetic retinopathy31. In this context, the authors suggested that the 
protective effects of the MR-409 could be mediated by its direct and/or GH-mediated action.
In the present study, MIA-690 and MR-409 have been also able to modulate emotional behaviors, in mice. 
We observed that both peptides induced anxiolytic and antidepressant-like effects following chronic treatment, 
without affecting locomotor activity (Figs. 4–7). The role of GH in regulation of mood is somewhat contradictory 
and little is known about the action of GHRH on brain functions. Human studies indicate that in adults with 
childhood onset GH deficiency, long term treatment with GH improves mood and memory34. On the other hand, 
somatostatin, which inhibits the release of several hormones, including GH, reduces anxiety-like behavior35,36. 
Mood disorders might be related to GH deficiency37,38, however the anxiolytic-antidepressant effects of a GHRH 
antagonist, MZ-4-71, suggests that GHRH itself may be involved in control of behavior20,25–27. Similarly, our 
research group described anxiolytic and antidepressant-like behavior in both young and old mice with general-
ized ablation of the GHRH gene21,39,40. Thus, we can hypothesize that the beneficial behavioral effects of MIA-690 
and MR-409 could be at least in part related to their antinflammatory and antioxidant effects (Figs. 8, 9), also 
described in different reports14,30–33. On the other hand, inflammation and oxidative stress are linked to a number 
NE DA 5-HT
Vehicle 0.09 ± 0.02 0.70 ± 0.18 0.34 ± 0.02
MIA-690 0.85 ± 0.05***,## 0.72 ± 0.00 6.38 ± 1.32***,##
MR-409 0.32 ± 0.50** 0.77 ± 0.11 4.19 ± 0.23**
Table 1. Aminergic neurotransmitter levels (ng/mg wet tissue) in prefrontal cortex. Data are expressed 
as means ± S.E.M. and subjected to analysis of variance (ANOVA) followed by Bonferroni post-hoc test 
**p < 0.005,***p < 0.001 vs. vehicle; ##p < 0.005 vs. MR-409 treated mice.
Figure 8. Relative quantification of gene expression of NF-kB, TNF-α and IL-6 (n = 9 for each group 
of treatment) in prefrontal cortex. Data were calculated using the 2−ΔΔCt method, normalized to β-actin 
mRNA levels, and expressed relative to control (calibrator sample, defined as 1.00). Data are expressed as 
means ± S.E.M. and analyzed by analysis of variance (ANOVA) followed by Bonferroni post-hoc test *p < 0.05 
**p < 0.01 vs. vehicle group; #p < 0.05 vs. MR-409 treated mice.
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of chronic diseases, including cancer, cardiovascular diseases, aging, neurodegenerative, and psychiatric disor-
ders, such as anxiety and depression40–43. The activation of the inflammatory and oxidative stress response leads 
to the release of inflammatory cytokines and mobilization of immune cells that can get access to brain42,43. In par-
ticular, some studies have demonstrated an increase in pro-inflammatory markers, such as NF-kB, IL-1 and IL-6, 
in anxiety- and depression-related conditions44–46. In addition, major depression and posttraumatic stress disor-
der are characterized by an increased activity of pro-oxidants over antioxidants47,48. Cytokines and their signaling 
pathways have significant effect on the metabolism of multiple neurotransmitters such as 5-HT and DA through 
impact on their synthesis, release and reuptake. Through their effects on neurotransmitter systems, cytokines lead 
to significant changes in motor activity and motivation as well as anxiety, arousal and alarm49. In this context, we 
also evaluated monoamine levels and NF-kB, TNF-α and IL-6 gene expression in prefrontal cortex of mice, after 
chronic administration with MIA-690 and MR-409. We observed an increase of NE and 5-HT levels, paralleled by 
a decrease of inflammatory markers in both MIA-690 and MR-409 treated mice (Table 1; Fig. 8, panel A, B and C). 
In agreement, the anxiolytic-antidepressant activity of MZ-4-71 was previously suggested to be mediated by α1/
α2-adrenergic and 5-HT1/5-HT2 serotonergic receptors25,26. Because several studies established a link between 
oxidative stress, anxiety and depression, we investigated the expression of Nrf2 in prefrontal cortex by immuno-
histochemistry. Nrf2 is a key transcription factor controlling various homoeostatic processes, at cellular level, in 
response to oxidative stress and toxic stimuli50 and regulating oxidative/xenobiotic stress response, also repressing 
inflammation51. Activation of Nrf2 results in up-regulation of cytoprotective and antioxidant enzymes-proteins 
Figure 9. Haematoxylin-eosin staining and immunohistochemical analysis of Nrf2 expression in mouse 
prefrontal cortex exposed to subcutaneous chronic treatment for 4 weeks (n = 9 for each group of treatment). 
(A) Haematoxylin-eosin staining (a) positive control (ctrl); (b) mice treated with MIA-690; (c) mice treated with 
MR-409. Scale bar: 100 µm, magnification 20x. (B) Immunohistochemical detection of Nrf2 expression in mice 
exposed to subcutaneous chronic treatment (a) positive control (ctrl); (b) mice treated with MIA-690; (c) mice 
treated with MR 409; (d) negative ctrl; Insert shows Nrf2 nuclear staining; arrows indicate Nfr2 positive area. 
Scale bar: 100 µm, magnification 20x. (C) Graphic representation of the percentage of Nrf2 positive area ( ± SD); 
densitometric analysis determined by direct visual counting of ten fields for each of three slides per sample. 
*p < 0.05 and **p < 0.01 vs. ctrl; #p < 0.01 vs. MR-409.
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in brain, by protecting against oxidative stress, in the brain50,51. Less Nfr2 signaling could reflect a “normalization” 
of oxidative parameters also evidenced from the molecular markers.
We found a significant increase of positive area percentage for Nrf2 in MIA-690 or MR-409 treated mice, 
suggesting an evident Nrf2 activation (Fig. 9). Surprisingly, both the agonist and the antagonist peptides induced 
similar effects in all experimental paradigms. However, we observed a higher efficacy of MIA-690 compared to 
MR-409. An accurate behavior analysis showed that MIA-690 was able to modulate emotional behavior begin-
ning from week 2 of treatment, while MR-409 induced significant behavioral change only at week 4 of treatment. 
At the end of treatment, we found a reduction of P GHRH-R gene and protein expression in MR-409 treated mice 
(Figs. 10, 11) (Supplementary Figs. S1 and S2). As previously observed by Schally et al.16, our results confirmed 
that chronic administration of MR-409 results in a down-regulation of P GHRH-R, which could justify the effects 
of MR-409 on emotional behavior. On the other hand, we can not rule out the possible involvement of other 
mechanisms in emotional behavior induced by the peptide.
In conclusion, both MIA-690 and MR-409 exhibit antinflammatory and antioxidant effects in ex vivo 
and in vivo experimental models. Surprisingly, both agonist and antagonist peptides induce anxiolytic and 
antidepressant-like behavior, which could be related to increased cortical NE and 5-HT levels, along with mod-
ulatory effects on the inflammatory and oxidative status. Further investigations are needed to confirm a role for 
GHRH analogs in mood disorders.
Methods
Peptides and chemicals. The GHRH antagonist MIA-690 and agonist MR-409 were synthesized by R.C. and 
W.S. in the laboratory of one of us (A.V.S.). For ex vivo studies, the peptides were dissolved in DMSO to form a 5 mM 
solution, and then further diluted to the concentration indicated. For in vivo studies, the peptides were dissolved in 
an aqueous solution of 0.1% DMSO (Sigma) and 10% propylene glycol (Sigma-Aldrich, St. Louis, MO)16,28.
Figure 10. Relative quantification of P GHRH-R gene expression (n = 9 for each group of treatment). Data 
were calculated using the 2−ΔΔCt method, normalized to β-actin mRNA levels, and expressed as relative to 
control (calibrator sample, defined as 1.00). Data are expressed as means ± S.E.M. and analyzed by analysis of 
variance (ANOVA) followed by Bonferroni post-hoc test **p < 0.005 vs. vehicle and MIA-690 treated mice.
Figure 11. Protein expression for P GHRH-R in mouse prefrontal cortex exposed to subcutaneous chronic 
treatment for 4 weeks (n = 3 for each group of treatment), assessed by Western blot. Actin served as internal 
control. Data are expressed as means ± S.E.M. and analyzed by analysis of variance (ANOVA) followed 
by Bonferroni post-hoc test.*p < 0.05 vs vehicle. The grouping of gels is cropped from different parts from 
different gels.
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Animals. Adult C57/BL6 male mice (3 month- old, weight 20–25 g, n = 48) were housed in plexiglas cages 
(2–4 animals per cage; 55 × 33 × 19 cm) and maintained under standard laboratory (21 ± 2 °C; 55 ± 5% humid-
ity) on a 14/10 h light/dark cycle, with ad libitum access to water and food. Only male mice were used to avoid 
any possible involvement of hormonal changes in adult female mice. Mice were fed with a standard rodent chow 
(Prolab RMH2500, PMI Nutrition International, Brentwood, MO). Housing conditions and experimentation pro-
cedures were strictly in agreement with the European Community ethical regulations (EU Directive n. 26/2014) 
on the care of animals for scientific research. In agreement with the recognized principles of “Replacement, 
Refinement and Reduction of Animals in Research”, prefrontal cortex specimens were obtained as residual mate-
rial from vehicle-treated mice randomized in our previous experiments approved by Local Ethical Committee 
(‘G. d’Annunzio’ University, Chieti-Pescara) and Italian Health Ministry (Project n. 885/2018-PR).
Ex vivo studies. Mice were sacrificed by CO2 inhalation (100%CO2 at a flow rate of 20% of the chamber vol-
ume per min), then brains were rapidly removed. The brains were cut into blocks containing the entire prefrontal 
cortex, frozen on dry ice, and stored at −80 °C before serial cryosectioning at a section thickness of 100 μm. A 
stereotaxic atlas of the mouse brain (Paxinos and Watson) was used during the cryosectioning procedure52. Tissue 
slices were maintained in a humidified incubator with 5% CO2 at 37 °C for 4 h (incubation period), in RPMI 
buffer with added bacterial LPS (10 μg/mL), as previously described53. During the incubation period, the tissues 
were treated with MR-409 or MIA-690 (1–5 μM). Tissue supernatants were collected and PGE2 and 8-iso-PGF2α 
levels (pg/mg wet tissue) were measured by RIA, as previously reported54. Briefly, specific anti-PGE2 and anti-
8-iso-PGF2α were developed in the rabbit; the cross-reactivity against other prostanoids was <0.3%. One hun-
dred microliters of prostaglandin standard or sample was incubated overnight at 4 °C with the 3H-prostaglandin 
(3000 cpm/tube; NEN) and antibody (final dilution: 1:120 000; kindly provided by the late prof. G. Ciabattoni), in 
a volume of 1.5 mL of 0.025 M phosphate buffer. Free and antibody-bound prostaglandins were separated by the 
addition of 100 μL 5% bovine serum albumin and 100 μL 3% charcoal suspension, followed by centrifugation for 
10 min at 4000 g at 5 °C and decanting off the supernatants into scintillation fluid (UltimaGold™, Perkin Elmer) 
for β emission counting. The detection limit of the assay method was 0.6 pg/mL.
Tissue supernatants were also assayed for nitrite determination by Griess assay, as previously described55. 
Briefly, nitrite production was determined by mixing 50 μL of the assay buffer with 50 μL of Griess reagent (1.5% 
sulfanilamide in 1 M HCl plus 0.15% N-(1-naphthyl) ethylenediamine dihydrochloride in distilled water, v/v). 
After incubation for 10 min, at room temperature, the absorbance at 540 nm was determined and nitrite concen-
trations were calculated from a standard curve for sodium nitrite.
Tissue supernatants were also assayed for lactate dehydrogenase (LDH) activity55. LDH activity was meas-
ured by evaluating the consumption of NADH in 20 mM HEPES-K + (pH 7.2), 0.05% bovine serum albumin, 
20 μM NADH and 2 mM pyruvate using a microplate reader (excitation 340 nm, emission 460 nm) according 
to manufacturer’s protocol (Sigma-Aldrich, St. Louis, MO). LDH activity was measured by evaluating the con-
sumption of NADH in 20 mM HEPES-K + (pH 7.2), 0.05% bovine serum albumin, 20 μM NADH and 2 mM 
pyruvate using a microplate reader (excitation 340 nm, emission 460 nm) according to manufacturer’s protocol. 
Nitrite and LDH production data were expressed as relative variations compared to vehicle-treated specimens. 
Immediately after sacrifice, prefrontal cortex was rapidly removed, dissected and stored in RNAlater solution 
(Ambion, Austin, TX) at −20 °C until further processed. Total RNA was extracted from the prefrontal cortex 
using TRI Reagent (Sigma-Aldrich), according to the manufacturer’s protocol. One microgram of total RNA 
extracted from each sample in a 20 μl reaction volume was reverse transcribed using High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). The samples were incubated in a 2720 Thermal Cycler (Applied 
Biosystems) initially at 25 °C for 10 min, then at 37 °C for 120 min, and finally at 85 °C for 5 s. Gene expression of 
COX-2, NF-kB and iNOS was determined by quantitative real-time PCR using TaqMan probe-based chemistry 
(Applied Biosystems), as previously described56,57. PCR primers and TaqMan probes were obtained from Applied 
Biosystems (Assays-on-Demand Gene Expression Products, Mm00478374_m1 for COX-2 gene, Mm00476361_
m1 for NF-kB gene, Mm00440502_m1 for iNOS gene, Mm00607939_s1 for β-actin gene. β-actin was used as the 
housekeeping gene. Gene expression data were calculated as previously reported58.
In vivo studies. After 2-week acclimation, mice were randomized into three groups and treated daily for 4 
weeks by subcutaneous administration of GHRH antagonist MIA 690 (5 μg), GHRH agonist MR 409 (5 μg) or 
vehicle solution18. All solutions were prepared freshly before use.The doses were selected based on previous stud-
ies including oncology. Injection volume was 0.1 ml for s.c. injection16,18. The animals were brought into the 
experimental room 30 min prior to the test in order to acclimate to the environment, and were kept in the testing 
chamber for 5 min prior to each test.
All treatments were administered at 09:00 am, and the experiments performed between 10:00 and 12:00 am. 
Each test session was recorded by a video camera connected to a computer; a single video frame was acquired 
with a highly accurate, programmable, monochrome frame grabber board (Data TranslationTM, type DT3153). 
The intelligent software Smart version 2.5 (Panlab, sl Bioresearch and Technology, Barcelona, Spain) was used for 
data processing. The apparatuses were purchased from 2 Biological Instruments (Besozzo VA, Italy)21,39. At the 
end of each test, the animals were returned to their home cages, and the apparatus was cleaned with 75% ethanol 
and dried before the next procedure. The behavioral parameters were recorded at 2 and then 4 weeks after the first 
treatment. Each test was conducted on the same group of animals (n = 18 animals for each group of treatment), 
after a 2 weeks rest period to avoid any interference on behavioral test performance, as previously reported21.
Locomotor activity. Locomotor activity was recorded in the home cage over 10 min. The activity monitor 
consisted of a black and white video camera, mounted in the top-centre of a cage (35 × 20 × 13 cm), positioned 
in the enclosure. Measurements used to assess locomotor activity were horizontal activity and vertical activity59.
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Light–dark exploration test. The light–dark box test assesses bright-space related anxiety59,60 and consists 
of two compartments (10 × 15 × 20 cm, each), dark and light ones, separated by a wall pierced with an open door. 
The dark compartment has opaque black walls, while the light compartment is transparent to light. Mice were 
placed in the black compartment, and time spent by the animal in the light compartment, latency of first exit from 
dark compartment, and number of transitions between compartments were recorded during a 10 min interval.
Elevated plus maze test. The apparatus consisted of two open arms and two closed arms that extended 
from a common central platform, elevated to a height of 45 cm above floor level and mice were individually placed 
in the centre of the maze facing an open arm40,61. The time spent on open arms, the latency to first exit and the 
number of transitions between the arms were recorded during a 10 min test period.
Tail suspension test. This test is well characterized for assessing antidepressant-like activity. Mice were 
individually suspended by the tail to a horizontal bar (at the height of 30 cm from floor) using adhesive tape. 
Immobility time was recorded during a 6 min period. Mice were considered immobile only when they hung 
passively and completely motionless21,39.
Prefrontal cortex monoamine extraction and high performance liquid chromatography (HPLC) 
determination. Immediately after sacrifice, brains were rapidly removed and prefrontal cortex were dis-
sected and subjected to biogenic amine extractive procedures. Thereafter, samples were analyzed by HPLC cou-
pled to electrochemical detection consisting of ESA Coulochem III detector equipped with ESA 5014 B analytical 
cell (selected potentials: electrode 1:−150 mV; electrode 2: +300 mV), as previously reported40,59. Monoamine 
levels were expressed as ng/mg wet tissue.
RNA extraction, reverse transcription and real-time reverse transcription polymerase chain 
reaction (PCR-RT). Prefrontal cortex was rapidly removed, dissected and stored in RNAlater solu-
tion (Ambion, Austin, TX) at −20 °C until further processed as previously described. Gene expression of 
NF-kB, TNF-α, IL-6 and P GHRH-R was determined by quantitative real-time PCR using TaqMan probe-based 
chemistry (Applied Biosystems, Foster City, CA, USA). PCR primers and TaqMan probes were obtained from 
Applied Biosystems (Assays-on-Demand Gene Expression Products, Mm00476361_m1 for NF-kB gene, 
Mm00443258_m1 for TNF-α gene, Mm00446190_m1 for IL-6 gene, Mm01326479_m1 for P GHRH-R gene, 
Mm00607939_s1 for β-actin gene. β-actin was used as the housekeeping gene. Gene expression data were calcu-
lated as previously reported58.
Light microscopy analysis and immunohistochemistry. Prefrontal cortex was fixed in 10% 
phosphate-buffered formalin for 2.5 hours. Each tissue block was dehydrated in a series of alcohol solutions of 
50%, 70%, 96% and 99% and then in Bioclear. Samples were then paraffin-embedded and cut into 7 μm-thick 
sections. Sections were de-waxed (Bioclear and alcohol in progressively lower concentrations), rehydrated and 
processed for haematoxylin-eosin and for anti-Nrf2 immunohistochemical analysis according to manufacturer 
protocol. Primary antibody anti-Nfr2 (rabbit polyclonal, sc-722, Santa Cruz Biotechnology, CA, USA) was 
applied for 2 hours at room temperature and diluted 1:200 in PBS. The immunohistochemical reactions was 
revealed with Rabbit specific HRP/DAB detection IHC kit (ab236469). Peroxidase reaction was developed using 
diaminobenzidine (DAB) chromogen and nuclei were counterstained with haematoxylin. Lastly, sections were 
dehydrated, cleared with xylene and mounted in Bio Mount (Bio Optica, Milano, Italy). Negative control was 
performed by omitting the primary antibody. Samples were then observe by means of LEICA DM 4000 light 
microscopy (Leica Cambridge Ltd., Cambridge, UK) equipped with a Leica DFC 320 camera (Leica Cambridge 
Ltd.) for computerized images62,63.
Western blot analysis. Cortex samples obtained from mice treated or not with MIA-690 or MR-409 were 
homogenized in RIPA buffer (Sigma-Aldrich), sonicated and centrifuged at 14,000 rpm (4 °C for 15 min). Total pro-
tein lysates were quantified with Bicinchoninic Acid kit (BCA) from Sigma-Aldrich. Proteins (35 μg) were separated 
by 10% SDS-PAGE, transferred to a nitrocellulose membrane and incubated overnight at 4 °C with the specific P 
GHRH-R antibody (dilution 1:500, rabbit polyclonal P GHRH-R antibody, Abcam, ab76263). Blots were reprobed 
with actin (dilution 1:500, mouse monoclonal actin antibody, Santa Cruz Biotechnology, sc-376421) for protein 
normalization. Immunoreactive proteins were visualized using horseradish peroxidase-conjugated goat anti-mouse, 
goat anti-rabbit or mouse anti-goat (1:4000) secondary antibodies by enhanced chemiluminescence substrate (ECL) 
using ChemiDoc XRS (Bio-Rad), densitometric analysis was performed with Quantity One software (Bio-Rad)18.
Statistical analysis. Statistical analysis was performed using GraphPad Prism version 5.01 for Windows 
(GraphPad Software, San Diego, CA, USA). All data were collected from each of the animals used in the exper-
imental procedure and means ± SEM were determined for each experimental group and analyzed by two way 
analysis of variance (ANOVA) followed by Bonferroni post-hoc test. F values are referring to repeated measure 
2-way ANOVA. As for gene expression analysis, 1.00 (calibrator sample) was considered the theoretical mean 
for the comparison. Statistical significance was accepted at p < 0.05. As regards gene expression analysis, the 
comparative 2−ΔΔCt method was used to quantify the relative abundance of mRNA and then to determine the rel-
ative changes in individual gene expression (relative quantification)58. Finally, as regards the animals randomized 
for each experimental group, the number was calculated on the basis of the ‘Resource Equation’ N = (E + T)/T 
(10 ≤ E ≤ 20)64 according to the guidelines suggested by the ‘National Centre for the Replacement, Refinement 
and Reduction of Animals in Research’ (NC3RS) and reported on the following web site: https://www.nc3rs.org.
uk/experimental-designstatistics.
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